LaminB1抗体—艾普蒂

+ +

•  

   

     All lanes use AB0054 Lamin B1 Antibody at 1:10000 dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use AB0054 Lamin B1 Antibody at 1:10000 dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use AB0054 Lamin B1 Antibody at 1:10000 dilution for 1 hour at room temperature.    

  
  

•  

   

     Immunofluorescent analysis of HepG2 cells, using Lamin B1 Antibody.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human non-Hodgkin's lymphoma, using the Antibody at 1:100 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human glioblastoma, using the Antibody at 1:100 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded Human prostate cancer, using the Antibody at 1:100 dilution.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded rat liver, using Lamin B1 Antibody.    

  
  

Lamin B1 is a key structural protein component of the nuclear lamina, a mesh-like layer underlying the inner nuclear membrane. It belongs to the type B lamin family, which is expressed in most somatic cells and plays critical roles in maintaining nuclear integrity, chromatin organization, and gene regulation. Unlike A-type lamins, Lamin B1 is constitutively expressed throughout the cell cycle and is essential for proper nuclear envelope assembly during mitosis. Its dysregulation has been linked to cellular senescence, aging-related disorders, and diseases such as cancer, neurodegenerative conditions, and progeroid syndromes.

Antibodies targeting Lamin B1 are widely used as research tools to study its expression, localization, and functional roles. These antibodies enable detection via techniques like Western blotting, immunofluorescence, and immunohistochemistry, providing insights into nuclear morphology changes during apoptosis or senescence (e.g., Lamin B1 downregulation is a biomarker of senescence). They also help investigate pathological mechanisms, such as altered nuclear shape in laminopathies or cancer metastasis. Commercial Lamin B1 antibodies are typically raised against specific epitopes, often within the N-terminal or rod domains, with validation across species (human, mouse, rat). Researchers must verify antibody specificity using knockout controls, as cross-reactivity with other lamin isoforms (e.g., Lamin B2) may occur. Studies utilizing these antibodies have significantly advanced understanding of nuclear architecture and disease pathogenesis (Coates et al., 2013; Shimi et al., 2008).